Group items tagged

'Digital' has become an important part of the everyday life. Digital healthcare plays a key role in the overall business strategy, and is going to change the world dramatically, affecting all businesses and modes of life.

The current competitive environment demands tactful management of most respected and skilled physicians by the healthcare organisations. Hence each healthcare organisation is making an ardent effort to ensure that no stone remains untouched. The fact of matter is not only true for the health care industry, but also for pharmaceutical companies.

GlaxoSmithKline (GSK) announced the expansion of its manufacturing facility in Boronia, in the outer eastern suburbs of Melbourne, Australia, in November 2014. The expansion will introduce the latest machinery, which will be used for manufacturing advanced aseptic packing of sterile pharmaceutical liquids.

Pharma Lab equipment, instruments Manufacturer, Exporter, Suppliers of mini models for r&d labs, main motor drives, universal gear for all purpose, coating, filling & dosing equipments, granulating, grinding attachments, homogenizing attachments, kneading attachments, mixing attachments, pelletizing attachments, sieves analysis attachments, stirring attachments, friability tester, single punch mini tablet press, rotary tablet press mini model, dies and punches, rapid mixer granulator, mini fluid bed unit, capsul filling, colloid mill - Ahmedabad, Gujarat, India.

Chindex International has entered into a definitive merger agreement with a buyer consortium of an affiliate of TPG, an affiliate of Shanghai Fosun Pharmaceutical (Group)

PBR Staff Writer Published 24 February 2014 US-based biotechnology firm Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) of its Kalydeco (ivacaftor) for the treatment of people with cystic fibrosis (CF).

Pharmacoeconomics (PE), a sub discipline of health economics, evaluates the behaviour of individuals, firms, and markets relevant to the use of pharmaceutical products, services, and programs, and with the focus on the costs (inputs) and consequences (outcomes) of that use.

Medical writing conveys clinical findings from research labs to the masses in form of articles for publication, regulatory documents, and content development for pharma-healthcare magazines, newsletters and websites. The criteria of writing the medical content mainly depends upon the need of the end users for examples documents for the medical journals, physicians, healthcare organisations, pharmaceutical companies, etc.

Medical-marketing or pharma-marketing is a term used for implementing the advertising strategies by pharmaceutical/biotech/medical device organizations for the promotion of their brands and products and meet the sales target. Besides, it also helps to regularly update the pharma-healthcare professionals about safe and effective use of the new drugs and devices available in the market.

Clinically validated data is a valuable asset to pharmaceutical organization. Data from the clinical trials are vital to the whole clinical development procedure. Value of any drug cannot be properly noticed until the clinical data is systematically organised, simply accessible and cleaned.

Epic Sciences has announced an agreement with Laboratory Corporation of America Holdings (LabCorp) to expedite sample processing for Epic's circulating tumor cell (CTC) technology to support European clinical trials.

Immuneering has entered into an agreement to expand its existing relationship with Bristol-Myers Squibb (BMS) for the use of Immuneering's proprietary computational biology methods to identify biological insights that would help in the discovery and development of medicines.

Germany-based OctreoPharm Sciences has received Orphan Drug Designation from the European Medicines Agency (EMA) for OPS202 as a diagnostic agent for the management of patients with gastro-entero-pancreatic-neuroendocrine tumors

US-based developer of new immunotherapeutics, including a portfolio of checkpoint modulators, anti-cancer vaccines and adjuvants, Agenus has completed the acquisition of Switzerland-based biopharmaceutical firm 4-Antibody.

Published 25 February 2014 Cambridge Healthtech Associates (CHA) has announced a new program to accelerate innovation in life sciences and health care. Announcing the launch of the first-ever tool in life sciences and health care to evaluate and rank new technologies and services via an end-user process.

PBR Staff Writer Published 25 February 2014 Bristol-Myers Squibb (BMS) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational DCV Dual Regimen (daclatasvir and asunaprevir) for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection (HCV).

PBR Staff Writer Published 21 February 2014 Israel-based Pluristem Therapeutics has submitted its application to the US Food and Drug Administration seeking Orphan Drug Designation for its PLacental eXpanded (PLX-PAD) cells for the treatment of severe preeclampsia.

US-based KYTHERA Biopharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for ATX-101 (deoxycholic acid) as an injectable treatment for the reduction of submental fat, which commonly presents as a double chin.

Fycompa (perampanel), the first in an entirely new class of treatment for partial onset seizures (the most common form of epilepsy), will be launched in the Netherlands on 13 May 2014.

A pioneering study looking into the possibility of combining existing therapies to slow down cancer growth is showing encouraging early results. Elly Earls reports. A first-of-its-kind medical study at The Care Oncology Clinic on Harley Street, London, has started work on evaluating whether the use of a combination of safe, tolerable, existing, generic therapies could slow down cancer growth and improve survival times in patients for whom other treatments are no longer available or working.